Enlicitide vs HS-10510

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Enlicitide · Lipfendra

Marketed by Merck & Co.

Phase 3 in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT05952856 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.

Next expected readout: November 2027 · NCT07821944 (registry estimate)

Reported efficacy

Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)

Result source: NCT05952856

HS-10510

Developed by Hansoh Pharmaceutical Group

Phase 1 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnlicitideHS-10510
LDL-C, % change-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
—Not reported
Non-HDL-C, % change-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
—Not reported
ApoB, % change-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
—Not reported
Lp(a), % change-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
—Not reported
3-point MACE (% with event)—Not posted · NCT07216482—Not reported

LDL-C, % change

Enlicitide
-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
HS-10510
—Not reported

Non-HDL-C, % change

Enlicitide
-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
HS-10510
—Not reported

ApoB, % change

Enlicitide
-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
HS-10510
—Not reported

Lp(a), % change

Enlicitide
-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
HS-10510
—Not reported

3-point MACE (% with event)

Enlicitide
—Not posted · NCT07216482
HS-10510
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HS-10510: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Enlicitide: 3 of 4 rows · HS-10510: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnlicitide
Dropout rate
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
3%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
1%Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
—
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Serious AEs
9.9%20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
4.5%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
3.9%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
1.3%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 9.4% (placebo 7.9%)
influenza 8.4% (placebo 8.9%)
accidental overdose 7.9% (placebo 4%)
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 9 more results
20 mg
accidental overdose 0%
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
30 mg
covid-19 5.3% (placebo 9.3%)
arthralgia 2.6% (placebo 1.3%)
nausea 2.6% (placebo 0%)
NCT05261126 · Phase 2 · registry result, not featured evidence
18 mg
covid-19 6.6% (placebo 9.3%)
nausea 5.3% (placebo 0%)
diarrhoea 3.9% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
12 mg
dyspepsia 6.6% (placebo 1.3%)
arthralgia 5.3% (placebo 1.3%)
fatigue 3.9% (placebo 6.7%)
NCT05261126 · Phase 2 · registry result, not featured evidence
6 mg
covid-19 7.8% (placebo 9.3%)
diarrhoea 6.5% (placebo 1.3%)
dyspepsia 1.3% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
dry mouth 12.5%
hypertension 12.5%
animal bite 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 12.5%
orthostatic hypotension 12.5%
dry mouth 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Enlicitide

LDL-C -59.7% (n=73) vs 1.2% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 6 more results
-57.9% (n=74) vs 1.2% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-54.5% (n=75) vs 1.2% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-40% (n=75) vs 1.2% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-58.2% (n=198) vs 2.6% (n=96) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-55.3% (n=193) vs 8.7% (n=94) placebo @ 52wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-64.6% (n=101) vs -6.3% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Non-HDL-C -54.3% (n=73) vs 1.5% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 5 more results
-51.8% (n=74) vs 1.5% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-49% (n=76) vs 1.5% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-34.4% (n=74) vs 1.5% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-52.3% (n=198) vs 2.1% (n=96) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-58% (n=101) vs -5.2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo B -51.8% (n=74) vs 0% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 5 more results
-48.7% (n=74) vs 0% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-45.8% (n=75) vs 0% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-32.8% (n=76) vs 0% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-48.2% (n=197) vs 1.8% (n=97) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-54.6% (n=101) vs -5.4% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Lp(a -24.7% (n=196) vs -1.6% (n=96) placebo @ 24wk
percent change · % of baseline
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-26.2% (n=101) vs 8.1% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 70 and 50% Reduction 70.8% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
81.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 5.5 and 50 Pct Reduction 67.3% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
78.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Goal Attainment 90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk30 mg
responder rate · % of participants
NCT05261126 · Phase 2 · registry result, not featured evidence
show 3 more results
90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
85.5% (n=76) vs 9.3% (n=75) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
80.5% (n=77) vs 9.3% (n=75) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · HS-10510's landscape